The Committee adopted by consensus a positive opinion for an initial marketing authorisation application for Lydaxx (tulathromycin), from Vetoquinol, a new generic product for treatment and metaphylaxis of bovine respiratory disease, treatment of infectious bovine keratoconjunctivitis, treatment and metaphylaxis of swine respiratory disease and treatment of the early stages of infectious pododermatitis.
France’s National Agency for the Safety of Medicines and Health Products (ANSM) has published a warning about the use of nonsteroidal anti-inflammatory drugs (NSAIDs) in patients suffering from infectious diseases. ANSM issued the warning after analyzing almost 20 years of real-world safety data on the use of the NSAIDs ibuprofen and ketoprofen
This study assesses the solid-solid interactions between the commercial form of Ketoprofen (KET), a non- steroidal anti-inflammatory drug of the propionic acid class, and several widely used pharmaceutical excipients. The work was carried out on drug-excipient mixtures, in 1:1 (w:w) ratio, blended in an agate mortar at room temperature. The compatibility/incompatibility of KET with the proposed excipients was highlighted by the most commonly used analytic methods: differential scanning calorimetry (DSC), Fourier transformed infrared spectroscopy (FT-IR) and powder X-ray diffraction (PXRD). The interactions between KET and three of the excipients, namely Macrogol 6000, magnesium stearate dehydrate and lactose monohydrate were evidenced by DSC and further confirmed by FT-IR and PXRD analysis.